Vitruvias Therapeutics, an Auburn, AL-based finished-dose generic drug development company, has agreed to license an approved Potassium Chloride Extended release ANDA. The product will be manufactured by contract development and manufacturing organization (CDMO) Bora Pharmaceutical’s Zhunan site, which was recently acquired from Impax.
 
“As a 40-year veteran if this industry, I have toured many manufacturing facilities, and Bora’s Zhunan facility is one of the best I have ever seen,” said Carl Whatley, chief executive officer, Vitruvias. “Being a relatively new facility and having the responsibility and FDA approval for the manufacturing of Impax’s U.S. products, its size, quality systems, state-of-the-art high volume equipment and highly responsive personnel make it a logical choice for our portfolio of technically complex oral solids.”
 
Bobby Sheng, chief executive officer, Bora Pharmaceuticals,” said, “Bora Pharmaceuticals is honored to be in business with Vitruvias. Their experienced management team has a stellar track record of successful product launches and their pipeline of products has positioned the company for explosive growth. We are excited to show our large-scale solvent capabilities and to give Vitruvias a high-quality competitive product in the market. We look forward to a long-term relationship with them.”
 
Potassium Chloride Extended Release tablets are used to prevent or to treat low blood levels of potassium (hypokalemia). Current annual sales of all forms of Potassium Chloride Extended Release tablets totaled approximately 1.66 billion tablets through September 2018.
 
This is the first contract manufacturing agreement between Vitruvias and Bora.